newsfilter
← Latest News
GlobeNewswire·

Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update

Company on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval pathway in October 2025, supported by successful pre-NDA meetingExpect initial data from Phase 2 study of